CN1419563A - 肽衍生物 - Google Patents

肽衍生物 Download PDF

Info

Publication number
CN1419563A
CN1419563A CN01807077A CN01807077A CN1419563A CN 1419563 A CN1419563 A CN 1419563A CN 01807077 A CN01807077 A CN 01807077A CN 01807077 A CN01807077 A CN 01807077A CN 1419563 A CN1419563 A CN 1419563A
Authority
CN
China
Prior art keywords
arg
pro
phe
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01807077A
Other languages
English (en)
Chinese (zh)
Inventor
北田千惠子
西泽直城
日沼州司
细谷昌树
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN1419563A publication Critical patent/CN1419563A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
CN01807077A 2000-03-23 2001-03-22 肽衍生物 Pending CN1419563A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000087114 2000-03-23
JP87114/2000 2000-03-23
JP288891/2000 2000-09-19
JP2000288891 2000-09-19

Publications (1)

Publication Number Publication Date
CN1419563A true CN1419563A (zh) 2003-05-21

Family

ID=26588465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01807077A Pending CN1419563A (zh) 2000-03-23 2001-03-22 肽衍生物

Country Status (10)

Country Link
US (1) US7635751B2 (enExample)
EP (1) EP1270585B1 (enExample)
JP (1) JP4786047B2 (enExample)
KR (1) KR20020081466A (enExample)
CN (1) CN1419563A (enExample)
AT (1) ATE326478T1 (enExample)
AU (1) AU2001242749A1 (enExample)
CA (1) CA2403447A1 (enExample)
DE (1) DE60119714T2 (enExample)
WO (1) WO2001070769A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254540A (zh) * 2012-01-09 2014-12-31 安科治疗公司 Apj受体化合物
CN104436158A (zh) * 2013-09-22 2015-03-25 华中科技大学 Apelin-13在治疗糖尿病肾病中的应用
WO2026007692A1 (zh) * 2024-07-05 2026-01-08 浙江大学 Apelin-13多肽突变体

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063892A1 (en) * 2002-01-29 2003-08-07 Takeda Chemical Industries, Ltd. Use of apelin
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP1967210A4 (en) * 2005-12-20 2009-11-11 Takeda Pharmaceutical NEW APPLICATION OF APÉLINE
RU2303454C1 (ru) * 2006-06-22 2007-07-27 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Средство, нормализующее репродуктивную функцию у женщин, и способ его получения
EP1903052A3 (en) * 2006-07-28 2008-04-02 Faust Pharmaceuticals SA APJ receptor ligands and uses thereof
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
US9381229B2 (en) 2011-11-28 2016-07-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Pharmaceutical composition for use in the treatment of dysfunction associated with aging
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
EP3907237A1 (en) 2012-12-20 2021-11-10 Amgen Inc. Apj receptor agonists and uses thereof
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
GB201407532D0 (en) * 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
MA42145B1 (fr) 2015-05-20 2020-05-29 Amgen Inc Triazoles agonistes du récepteur apj
WO2017140684A2 (en) 2016-02-15 2017-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
EP3788037A1 (en) 2018-05-01 2021-03-10 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2118372T3 (es) * 1992-11-17 1998-09-16 Icos Corp Nuevos receptores siete transmembrana v28.
CN1283228A (zh) * 1997-12-24 2001-02-07 武田药品工业株式会社 多肽、其生产方法及应用
US6475718B2 (en) * 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
AU5759399A (en) * 1998-09-25 2000-04-17 Takeda Chemical Industries Ltd. Peptide derivative

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254540A (zh) * 2012-01-09 2014-12-31 安科治疗公司 Apj受体化合物
CN104436158A (zh) * 2013-09-22 2015-03-25 华中科技大学 Apelin-13在治疗糖尿病肾病中的应用
WO2026007692A1 (zh) * 2024-07-05 2026-01-08 浙江大学 Apelin-13多肽突变体

Also Published As

Publication number Publication date
CA2403447A1 (en) 2001-09-27
US7635751B2 (en) 2009-12-22
DE60119714T2 (de) 2006-09-07
JP4786047B2 (ja) 2011-10-05
AU2001242749A1 (en) 2001-10-03
WO2001070769A1 (fr) 2001-09-27
US20040116336A1 (en) 2004-06-17
JP2002167397A (ja) 2002-06-11
EP1270585A1 (en) 2003-01-02
EP1270585A4 (en) 2004-12-15
DE60119714D1 (de) 2006-06-22
ATE326478T1 (de) 2006-06-15
EP1270585B1 (en) 2006-05-17
KR20020081466A (ko) 2002-10-26

Similar Documents

Publication Publication Date Title
CN1283228A (zh) 多肽、其生产方法及应用
CN1035256C (zh) 新的多肽化合物的制备方法
CN1163599C (zh) 抗gpiib/iiia重组抗体
CN1232038A (zh) 新肽化合物和其制备方法及含有它们的药物组合物
CN1099801A (zh) 甲状旁腺素类似物，它们的生产方法和含有它们的药物组合物
CN1041950A (zh) 新型肽酶抑制剂
CN1328568A (zh) 肽衍生物
CN1155299A (zh) G蛋白偶联受体蛋白质及其产生方法和用途
CN1741814A (zh) 修饰的钠尿化合物、缀合物及其应用
CN1207126A (zh) G蛋白偶联受体蛋白的配体多肽及其生产方法和用途
CN1256147C (zh) Cd8作为细胞免疫系统的抑制剂
CN1311796A (zh) 肽类抗血管生成药
CN1165147A (zh) 鸟嘌呤核苷酸结合蛋白偶联受体蛋白质，其生产和应用
KR20020081466A (ko) 펩티드 유도체
CN1116305C (zh) 肽衍生物
CN1933848A (zh) 用于治疗性干预的y2选择性受体激动剂
CN101035806A (zh) 新的糊精家族多肽－6（afp－6）类似物和制备和使用它们的方法
CN1333786A (zh) 新的g蛋白偶联型受体蛋白、其dna及其配体
CN1549858A (zh) 内源和非内源型人g蛋白偶联受体
CN1161468C (zh) Mpl配体类似物
CN1633498A (zh) 新型胰岛素/胰岛素样生长因子/松弛素家族多肽及其dna
CN1168738C (zh) 生物素衍生物
CN1171400A (zh) 呫吨衍生物,其制备和用途
CN1139931A (zh) 环状神经激肽a拮抗剂
CN1177049C (zh) 编码具有抑制癌细胞生长功能的人蛋白的多核苷酸

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication